Glucotrack, Inc. (GCTK): Nasdaq/NYSE listing notice — GlucoTrack regains Nasdaq compliance after $10M public offering

Glucotrack, Inc.

Cured Nasdaq Rule 5550(b)(1) stockholders' equity deficiency below $2.5M minimum.
Raised ~$10M gross proceeds from April 17, 2023 firmly committed public offering.
Nasdaq will continue to monitor compliance; delisting risk remains if not maintained.
November 2022 notice triggered by Q3 2022 Form 10-Q equity shortfall.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Glucotrack, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

common stock with gross proceeds to the Company of approximately $10.0 million, before deducting underwriting discounts and other estimated expenses paid by the Company. The deficiency cured was the November 22, 2022 notice from Nasdaq that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) since its third quarter 2022 Form 10-Q reported stockholders’ equity under the $2.5 million required minimum. The Company acknowledges that Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of its next periodic r

View on SEC.gov

Browse all listing & compliance notices →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-018381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.